Insulin detemir
| Clinical data | |
|---|---|
| Trade names | Levemir |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a606012 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 60% (subcutaneous) |
| Elimination half-life | 5–7 hours |
| Duration of action | ≤ 24 hours |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C267H402N64O76S6 |
| Molar mass | 5916.89 g·mol−1 |
| (what is this?) (verify) | |
Insulin detemir, sold under the brand name Levemir among others, is a long-acting modified form of medical insulin used to treat both type 1 and type 2 diabetes.[6] It is used by injection under the skin.[6] It is effective for up to 24 hours.[6]
Common side effects include low blood sugar, allergic reactions, pain at the site of injection, and weight gain.[6] Use in pregnancy and breastfeeding appears safe.[7] It works by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.[6]
Insulin detemir was approved for medical use in the European Union in June 2004, and in the United States in June 2005.[5][6][8] It is on the World Health Organization's List of Essential Medicines.[9] In 2022, it was the 127th most commonly prescribed medication in the United States, with more than 4 million prescriptions.[10][11]
- ^ "Levemir FlexPen 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
- ^ "Levemir InnoLet 100 units/ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
- ^ "Levemir Penfill 100 units/ml solution for injection in cartridge - Summary of Product Characteristics (SmPC)". (emc). 21 May 2018. Retrieved 14 April 2020.
- ^ "Levemir- insulin detemir injection, solution". DailyMed. 24 March 2020. Retrieved 19 October 2020.
- ^ a b "Levemir EPAR". European Medicines Agency (EMA). 6 August 2009. Retrieved 14 April 2020.
- ^ a b c d e f "Insulin Detemir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ "Insulin detemir (Levemir) Use During Pregnancy". Drugs.com. 12 June 2019. Retrieved 14 April 2020.
- ^ "Drug Approval Package: Levemir Insulin Detemir[rDNA origin] Injection; NDA #021536". U.S. Food and Drug Administration (FDA). 26 July 2005. Archived from the original on 4 April 2015. Retrieved 14 April 2020.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- ^ "Insulin Detemir Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.